AbbVie’s Allergan reaches $2 billion opioid lawsuit settlement – Bloomberg News
2022.07.28 03:14
FILE PHOTO: A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid/File Photo
(Reuters) – AbbVie Inc (NYSE:ABBV)’s unit Allergan (NYSE:AGN) has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter.
The deal would settle more than 3,000 lawsuits filed by state and local governments, but complete terms of the settlement are still being chalked out, according to the report. Thousands of lawsuits have been filed against drugmakers, distributors and pharmacies over the U.S. opioid crisis.
Israel-based Teva Pharmaceutical Industries (NYSE:TEVA) on Tuesday announced a $4.35 billion proposed nationwide settlement of its U.S. opioid lawsuits.
AbbVie did not immediately respond to a Reuters request for a comment.
